Shots:

• GI Innovation has entered into a clinical trial collaboration & supply agreement with Merck to assess GI-102 + Keytruda for treating immunotx.-resistant liver cancer, melanoma & RCC. It has previously partnered for GI-101A with Merck
• Combination will be assessed under the P-II study to treat the 3 indications in patients resistant to immuno-oncology treatments. Study of GI-102 alone has achieved an ORR of 42.9% (3 PRs) in melanoma patients and tumor regression in 60% of mice in non-clinical liver cancer model
• The US sites such as Mayo Clinic (campuses in Rochester, Florida & Arizona), Cleveland Clinic & Memorial Sloan Kettering Cancer Center along with 14 South Korean hospitals will participate in the trial

Ref: Businesswire | Image: GI Innovation & Merck

Related News:- Roche’s Tecentriq SC Receives the EC’s Approval for Treating Various Cancers

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com